Published in Psychopharmacology (Berl) on February 18, 2005
Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine. Trends Pharmacol Sci (2009) 1.17
The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. Psychopharmacology (Berl) (2009) 1.13
Modulation of glutamatergic synaptic transmission in the bed nucleus of the stria terminalis. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.10
Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process. Learn Mem (2008) 0.90
Desipramine potentiation of the acute depressant effects of ethanol: modulation by alpha2-adrenoreceptors and stress. Neuropharmacology (2008) 0.85
Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology (Berl) (2009) 0.84
Norepinephrine and impulsivity: effects of acute yohimbine. Psychopharmacology (Berl) (2013) 0.81
Preclinical models of antipsychotic drug action. Int J Neuropsychopharmacol (2013) 0.79
Predator Stress-Induced CRF Release Causes Enduring Sensitization of Basolateral Amygdala Norepinephrine Systems that Promote PTSD-Like Startle Abnormalities. J Neurosci (2015) 0.79
Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats. Psychopharmacology (Berl) (2010) 0.79
Interactions between corticotropin-releasing factor and the serotonin 1A receptor system on acoustic startle amplitude and prepulse inhibition of the startle response in two rat strains. Neuropharmacology (2011) 0.78
Noradrenergic alpha-2 receptor modulators in the ventral bed nucleus of the stria terminalis: effects on anxiety behavior in postpartum and virgin female rats. Behav Neurosci (2013) 0.78
Rationale for iloperidone in the treatment of posttraumatic stress disorder. Innov Clin Neurosci (2014) 0.75
Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1mg/kg. Neurosci Lett (2015) 0.75
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) (2001) 4.03
Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology (1975) 2.76
Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) (1988) 1.80
Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology (2001) 1.61
Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies. Neuroscience (1988) 1.54
Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull (1990) 1.44
Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther (1994) 1.23
Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety (2002) 1.20
Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination. J Pharmacol Exp Ther (1992) 1.15
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res (2002) 1.04
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (1998) 1.03
M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology (1999) 0.98
Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats. Psychopharmacology (Berl) (1990) 0.97
5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther (1992) 0.95
Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science (1999) 0.93
The release of noradrenaline in the locus coeruleus and prefrontal cortex studied with dual-probe microdialysis. Brain Res (2001) 0.91
8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology (Berl) (1995) 0.88
Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology (1998) 0.87
Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA. Brain Res (1985) 0.87
Alpha2A-adrenoceptors are important modulators of the effects of D-amphetamine on startle reactivity and brain monoamines. Neuropsychopharmacology (2004) 0.86
Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther (1997) 0.86
Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.84
Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem Pharmacol (1993) 0.82
Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. Psychopharmacology (Berl) (2001) 0.80
5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology (Berl) (1996) 0.80
Antipsychotic drug affinities at alpha2-adrenoceptor subtypes in post-mortem human brain. J Psychopharmacol (1998) 0.79
The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats. Br J Pharmacol (1993) 0.78
Apomorphine, d-amphetamine, strychnine and yohimbine do not alter prepulse inhibition of the acoustic startle reflex. Psychopharmacology (Berl) (1988) 0.78
Spinal modulation of acoustic startle: opposite effects of clonidine and d-amphetamine. Psychopharmacology (Berl) (1981) 0.77
Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol Learn Mem (2008) 3.23
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry (2006) 1.93
A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry (2009) 1.69
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry (2003) 1.48
Studies in genetically modified mice suggest novel mechanisms of mood regulation. Biol Psychiatry (2010) 1.38
Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology (2006) 1.33
Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull (2008) 1.32
A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev (2007) 1.29
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One (2012) 1.28
Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry (2003) 1.28
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci (2004) 1.26
Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci (2002) 1.24
5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology (2009) 1.24
Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res (2009) 1.20
The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One (2009) 1.20
The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord (2010) 1.18
Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res (2003) 1.17
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology (2012) 1.17
Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev (2013) 1.16
The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol (2003) 1.15
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol (2006) 1.15
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) (2009) 1.14
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol (2013) 1.13
The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci (2010) 1.11
Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) (2003) 1.11
Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One (2009) 1.10
Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res (2004) 1.10
Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry (2008) 1.07
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology (2011) 1.06
Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res (2002) 1.06
Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology (2003) 1.05
Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis--a longitudinal study. Eur Arch Psychiatry Clin Neurosci (2004) 1.05
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull (2005) 1.04
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
Animal models of schizophrenia. Curr Top Behav Neurosci (2010) 1.04
Heart rate variability in bipolar mania and schizophrenia. J Psychiatr Res (2009) 1.03
Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res (2006) 1.03
Predator threat induces behavioral inhibition, pituitary-adrenal activation and changes in amygdala CRF-binding protein gene expression. Psychoneuroendocrinology (2006) 1.03
Repeated assessment of exploration and novelty seeking in the human behavioral pattern monitor in bipolar disorder patients and healthy individuals. PLoS One (2011) 1.02
Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) (2003) 1.02
The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav (2010) 1.02
Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res (2010) 1.02
CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues. Neuropsychopharmacology (2008) 1.02
Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice. Hum Mol Genet (2009) 1.01
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J Psychopharmacol (2011) 1.00
GABA-A and 5-HT1A receptor agonists block expression of fear-potentiated startle in mice. Neuropsychopharmacology (2002) 1.00
Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci (2005) 0.99
The challenge of connecting the dots in the B.R.A.I.N. Neuron (2013) 0.99
Action of modafinil--increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry (2010) 0.99
Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. Prev Chronic Dis (2012) 0.98
Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr Bull (2011) 0.98
Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci (2012) 0.97
The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res (2011) 0.97
Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res (2012) 0.97
Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol (2010) 0.97
Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Hum Mol Genet (2010) 0.97
Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev (2010) 0.97
The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behav Brain Res (2004) 0.97
Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol (2008) 0.97
Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biol Psychiatry (2002) 0.96
The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) (2006) 0.96
Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology (2007) 0.96
The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology (2004) 0.95
Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry (2002) 0.95
The acoustic startle reflex and its modulation: effects of age and gender in humans. Biol Psychol (2003) 0.95
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther (2006) 0.95
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology (2006) 0.95
Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology (2011) 0.95
Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex (2008) 0.95
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology (Berl) (2008) 0.95
Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology (2003) 0.95
Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil. Neuropsychopharmacology (2011) 0.94
Principles of motivation revealed by the diverse functions of neuropharmacological and neuroanatomical substrates underlying feeding behavior. Neurosci Biobehav Rev (2013) 0.93
Discrete forebrain neuronal networks supporting noradrenergic regulation of sensorimotor gating. Neuropsychopharmacology (2011) 0.93
Prepulse inhibition and "psychosis-proneness" in healthy individuals: an fMRI study. Eur Psychiatry (2008) 0.92
Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiatry (2005) 0.92
The effects of sex and neonatal maternal separation on fear-potentiated and light-enhanced startle. Behav Brain Res (2005) 0.92
Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology (Berl) (2002) 0.92
Corticotropin-releasing factor-1 receptors in the basolateral amygdala mediate stress-induced anorexia. Behav Neurosci (2005) 0.91
Four factors underlying mouse behavior in an open field. Behav Brain Res (2012) 0.91
Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology (2006) 0.91
Isolation rearing of mice induces deficits in prepulse inhibition of the startle response. Behav Brain Res (2006) 0.91
Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol (2012) 0.91
RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology (2003) 0.90
Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl) (2012) 0.90
Prolonged Ketamine Effects in Sp4 Hypomorphic Mice: Mimicking Phenotypes of Schizophrenia. PLoS One (2013) 0.90
Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. J Affect Disord (2013) 0.89
Reversal of startle gating deficits in transgenic mice overexpressing corticotropin-releasing factor by antipsychotic drugs. Neuropsychopharmacology (2003) 0.89
Disruption of prepulse inhibition after stimulation of central but not peripheral alpha-1 adrenergic receptors. Neuropsychopharmacology (2006) 0.89
Age-associated improvements in cross-modal prepulse inhibition in mice. Behav Neurosci (2010) 0.89
Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors. Behav Brain Res (2010) 0.88
Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl) (2013) 0.88
MDMA "ecstasy" alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology (Berl) (2004) 0.88
An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther (2005) 0.88